NO20071160L - Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel - Google Patents

Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel

Info

Publication number
NO20071160L
NO20071160L NO20071160A NO20071160A NO20071160L NO 20071160 L NO20071160 L NO 20071160L NO 20071160 A NO20071160 A NO 20071160A NO 20071160 A NO20071160 A NO 20071160A NO 20071160 L NO20071160 L NO 20071160L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
androgen deficiency
estrogen receptor
receptor modulator
selective estrogen
Prior art date
Application number
NO20071160A
Other languages
English (en)
Inventor
Risto Lammintausta
Taru Blom
Janne Komi
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/fi
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of NO20071160L publication Critical patent/NO20071160L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår anvendelse av en selektiv østrogenreseptormodulator, eller en isomer, isomerblanding, metabolitt eller et farmasøytisk akseptabelt salt derav for fremstilling av et farmasøytisk preparat for anvendelse i en fremgangsmåte for behandling eller forebygging av androgenmangel eller sykdommer og forstyrrelser forårsaket av androgenmangel hos et mannlig individ.
NO20071160A 2004-09-03 2007-03-01 Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel NO20071160L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
FI20041216A FI20041216A0 (fi) 2004-09-21 2004-09-21 Menetelmä androgeenivajeen hoitoon tai estoon
PCT/FI2005/000333 WO2006024689A1 (en) 2004-09-03 2005-07-20 Use of a selective estrogen receptor modulator for the manufacture of a pharmaceutical preparation for use in a method for the treatment or prevention of androgen deficiency

Publications (1)

Publication Number Publication Date
NO20071160L true NO20071160L (no) 2007-05-25

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071160A NO20071160L (no) 2004-09-03 2007-03-01 Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel

Country Status (10)

Country Link
EP (1) EP1786408A4 (no)
JP (1) JP2008511615A (no)
KR (1) KR20070059110A (no)
AU (1) AU2005279178A1 (no)
BR (1) BRPI0514701A (no)
CA (1) CA2578852A1 (no)
MX (1) MX2007002606A (no)
NO (1) NO20071160L (no)
RU (1) RU2007112114A (no)
WO (1) WO2006024689A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2121553T3 (pl) 2007-02-14 2012-11-30 Hormos Medical Ltd Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US9975832B2 (en) 2014-12-29 2018-05-22 Olon S.P.A. Process for the preparation of ospemifene and fispemifene
US20250205247A1 (en) * 2022-03-15 2025-06-26 Centre D'etude Des Cellules Souches Use of bazedoxifene for increasing muscle survival

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
WO2001091744A1 (en) * 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
CN1679956A (zh) * 2001-11-29 2005-10-12 Gtx公司 治疗因雄激素剥夺引起的症状

Also Published As

Publication number Publication date
AU2005279178A1 (en) 2006-03-09
EP1786408A4 (en) 2010-07-28
WO2006024689A1 (en) 2006-03-09
MX2007002606A (es) 2007-05-15
RU2007112114A (ru) 2008-10-10
CA2578852A1 (en) 2006-03-09
KR20070059110A (ko) 2007-06-11
JP2008511615A (ja) 2008-04-17
EP1786408A1 (en) 2007-05-23
BRPI0514701A (pt) 2008-06-24

Similar Documents

Publication Publication Date Title
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
NO20071160L (no) Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
WO2009068689A3 (en) Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
WO2014170755A3 (en) Sustained-release formulations of colchicine and methods of using same
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
NO20092584L (no) Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
ATE453642T1 (de) Substituierte phenylaminopyrimidine
DK1933833T3 (da) Terapi til behandling af overaktiv blære
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
NO20083836L (no) N-hydroksyakrylamidforbindelser
WO2007025005A3 (en) Sustained release formulations of nalbuphine
NO20080936L (no) Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
NO20074332L (no) Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser
WO2006119389A3 (en) Quinine-containing controlled-release formulations
WO2011047837A3 (de) Schmelzgranuliertes cinacalcet
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2007038506A3 (en) Method for the treatment of cachexia
ITFI20080024A1 (it) Metodo per la correzione incruenta dell'ipercifosi dorsale e tutore ortopedico per la sua attuazione.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application